M&A · Healthcare · Biological Products, (No Diagnostic Substances)
Sanofi to acquire Translate Bio, Inc.
Announced Aug 3, 2021 · Closed Sep 14, 2021
Deal value$3.20BEV $3.04B
Premium30.0%To unaffected price
EV / Adj. EBITDA—18.0x EV / Revenue
ConsiderationAll cash$38.00 per share
Transaction
- Acquirer
- Sanofi (SNY)
- Target
- Translate Bio, Inc.
- Buyer type
- Strategic
- Offer price per share
- $38.00
- Enterprise value
- $3.04B
- Status
- Closed Sep 14, 2021
Deal protections
- Break fee (target pays)
- $96.0M · 3.0%
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- —
Advisors
- To the acquirer
- Morgan Stanley
- To the target
- Centerview, Evercore
Sector context · Healthcare
- Comparable deals
- 22 in the prior 24 months
- Premium
- 30.0% vs. 45.0% sector median
- EV / Adj. EBITDA
- Sector median 19.3x
- Break fee
- 3.0% vs. 3.3% sector median
Timeline
- AnnouncedAug 3, 2021
- Tender offerAug 16, 2021
- ClosedSep 14, 2021